Core Insights - The "Synthetic Immunology and Vaccine Manufacturing Key Laboratory" has been officially established in Beijing, focusing on key issues in synthetic immunology and vaccine manufacturing [1] - Kangtai Biological, a leading company in the domestic vaccine industry, is deeply involved in the laboratory's construction, with a focus on integrating AI technology throughout the vaccine development process [1] - The laboratory aims to achieve breakthroughs in antigen design, adjuvant development, delivery systems, and quality control, addressing challenges in multi-valent vaccines and establishing a leading rapid response and intelligent manufacturing system [1] Group 1 - The laboratory is a collaboration between the Chinese Academy of Sciences, Kangtai Biological's wholly-owned subsidiary Minhai Biological, Xinzhi Biological, and Chengda Tianhe [1] - The laboratory will focus on two main directions: AI-assisted precise immunogen design and addressing pathogen variation challenges through AI structural vaccinology [1] - The goal is to achieve "one vaccine for multiple diseases," exemplified by the RSV-hMPV bivalent vaccine [1] Group 2 - The head of the laboratory, Academician Gao Fu, emphasized the combination of original innovation from the Chinese Academy of Sciences and the industrialization capabilities of the co-building enterprises to accelerate technology transfer [2] - The establishment of this collaborative platform is expected to inject new momentum into Kangtai Biological's innovation pipeline, particularly in multi-valent vaccines and therapeutic hepatitis B vaccines [2] - The deep application of AI technology is anticipated to shorten the R&D cycle and accelerate the market launch of innovative products [2]